Novo Nordisk's High-Dose Launch and AI Bet Aim to Revive Slumping Shares

Novo Nordisk launches potent Wegovy HD and partners with OpenAI, yet its stock is down over 50% from highs amid investor skepticism over 2026 guidance.

Novo Nordisk shares, closing at €34.47, find themselves caught in a stark contradiction. While the Danish pharmaceutical giant unleashes a flurry of strategic initiatives, its stock price languishes more than 50% below its 52-week high, down nearly 23% year-to-date. This disconnect between operational aggression and market sentiment defines the current chapter for the weight-loss drug leader.

The centerpiece of its offensive is now widely available in the United States. Wegovy HD, featuring a 7.2 mg dose of semaglutide, represents the highest potency injection the company has brought to market. Clinical data underpinning the launch is compelling: participants in the STEP-UP study lost an average of 20.7% of their body weight, with one-third shedding more than 25%. This marks a significant efficacy jump from the previous maximum dose, which achieved 17.5% weight loss. In a clear competitive move, Novo Nordisk has priced the monthly treatment at approximately $399 for cash-paying patients, undercutting key rival Eli Lilly by about 40%. With insurance discounts, some patients may pay as little as $25.

Beyond the pharmacy, the company is undergoing a profound operational transformation. After reducing its workforce by roughly 10%, or nearly 7,800 people, in 2025, management has sharply reversed course. This year, Novo Nordisk has already hired around 2,000 new employees, with approximately 1,400 already onboarded. The hiring spree focuses squarely on bolstering production and research capabilities for its core therapies.

A major partnership with OpenAI aims to accelerate innovation across the business. The collaboration, which complements an existing alliance with Nvidia around the Gefion supercomputer, will use artificial intelligence to analyze complex datasets and identify new drug candidates. Immediate pilot programs are launching in R&D, manufacturing, and sales, with a company-wide integration targeted by the end of 2026. The goal is to significantly shorten the timeline from discovery to regulatory approval.

Despite these efforts, investor skepticism runs deep. The stock's Relative Strength Index (RSI) reading of 25 indicates a severely oversold condition. Even a substantial share buyback program has provided limited support; of the up to 3.8 billion Danish kroner authorized for repurchase by early May, about 2.8 billion kroner has already been deployed. Analyst sentiment remains mixed. BMO Capital recently lowered its price target to $36, citing concerns that first-quarter sales of the Wegovy pill may disappoint. Jefferies maintains a "Hold" rating.

Management's own guidance for 2026 forecasts a decline in both sales and earnings, pressured by pricing dynamics and evolving political frameworks. This outlook contributes to a historically low valuation, with the forward price-to-earnings ratio sitting at just under 12. The dividend yield has consequently risen to 4.2%.

Looking ahead, investors seeking a catalyst are closely watching CagriSema, a combination therapy of cagrilintid and semaglutid, though its regulatory timeline remains unclear. A more immediate potential boost could arrive by mid-2026 if the US Medicare program decides to provide coverage for obesity medications, opening access to millions of new patients. For now, the market awaits evidence that the company's potent new dose and technological bets can translate into a sustained financial and share price recovery. Regulatory decisions for Wegovy HD in the European Union and United Kingdom are expected in the second half of 2026.